NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01543698 2024-03-13
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Pfizer
Phase 1/2 Completed
NCT01469130 2020-10-05
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Array BioPharma
Phase 1 Completed
NCT01352273 2020-09-30
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Array BioPharma
Phase 1 Completed
NCT01449058 2017-10-02
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
Phase 1 Completed